"AIMed" Brand Fully Upgraded: AIMed Injects AI Certainty into Every Drug Discovery

Hangzhou Huiyidao Technology Co., Ltd. (hereinafter referred to as "Huiyidao") has officially announced a comprehensive upgrade of its brand, vision, and mission. Huiyidao will continue to deeply explore the application value of AI in translational medicine under the new brand image of "AIMed" and will take "Enabling global translational medicine success through trusted AI" as its vision, striving to become the intelligent connector and enabler for global translational medicine. AIMed is bridging the gap from lab discoveries to clinical applications through artificial intelligence, allowing innovations to benefit lives more quickly.

 
Jin Xia
AIMed Founder and Chairman

Member of the Zhejiang Provincial Committee of the Chinese People's Political Consultative Conference

Chairman of Zhejiang Health Industry Big Data Technology Alliance

Vice Chairman of Zhejiang Province's Large Health Industry Association

Executive Vice Chairman and Secretary General of the Yangtze River Delta Data-Driven Innovative Biopharmaceutical Industry Chain Alliance

Xia Jin, Founder and Chairman of AIMedSaid: "Since its establishment in 2019, AIMed has relied on six years of accumulated medical knowledge, clinical and evidence-based data, global patent and technology intelligence data, molecular and biological structure data, etc. Combined with its self-developed large pharmaceutical vertical model and translational medicine knowledge graph, it is building trusted AI that deeply serves translational medicine scenarios. It has already launched AI Agent products for innovative drugs, generic drugs, and traditional Chinese medicine in overseas Freedom-to-Operate (FTO) scenarios. This brand upgrade is not only a visual change but also a reaffirmation of our commitment and vision to the life sciences industry — enabling the success of global translational medicine through trusted AI. From early drug research initiation, to clinical trials, to registration and market access, AIMed will ensure that all evidence and conclusions generated by related AI products are traceable, accurate, and professional.Inject AI's certainty into every drug discovery.”

Dr. Kaige Tian
Chief Product Officer of AIMed

Dr. Kaige Tian, Chief Product Officer of AIMedSaid: "PharmaMark AI, as the core Agent product of AIMed, addresses the high patent litigation risks faced by Chinese pharmaceutical companies expanding overseas. It identifies patent barriers in the early stages of R&D, completes compliance due diligence before entering foreign markets, and provides rapid support in competitive responses. By delivering definitive conclusions through highly specialized vertical AI, it mitigates compliance uncertainties associated with global expansion, significantly reducing infringement risks for pharmaceutical companies going abroad while increasing the success rate of translational medicine and financing valuations. To support more core scenarios in translational medicine, the AIMed R&D team will release additional Agent applications by 2026.With hardcore professional strength and AI technologyTo Provide Full Lifecycle Support for Translational Medicine。”

If you are facingConfusion about overseas compliance, FTO report requirements，Or want to knowFor details on the application of AIMed in specific scenarios such as innovative drugs, generic drugs, and traditional Chinese medicine, scan the code now to apply for a trial:

AIMed, founded in December 2019, is a pioneer enterprise with Medical AI technology at its core. It aims to integrate knowledge from the global life sciences domain with computer science theories to achieve an intelligent transformation of the translational medicine ecosystem. Operating through a global collaboration model, AIMed co-creates patented algorithms with top research institutions and has received authoritative certification from the U.S. FDA. As a leading practitioner and explorer of AI Agent products for translational medicine scenarios in China and globally, AIMed's PharmaMark AI product series has been adopted by multiple national regulatory agencies and is gradually becoming an essential component in pharmaceutical companies' translational medicine workflows.